Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Fig. 3

High numbers of S100A8/A9 expressing cells are associated with short-term overall survival. a Dot plot showing the percentage of S100A8/A9 positive cells in primary melanoma tissue sections of long-term (LT) and short-term (ST) survivors. b Dot plot showing the percentage of S100A8/A9 positive cells in metastatic melanoma tissue sections of LT- and ST-survivors. The plots depict data from the tissue microarrays TMA2 and TMA3. Black horizontal lines indicate median and quartile percentages of S100A8/A9 positive cells. c-f Kaplan-Meier survival curves for overall survival stratified by the percentage of S100A8/A9 positive cells (≤55% vs. > 55%) in the primary melanoma samples of TMA2 (c) and TMA3 (e), and in the metastatic melanoma samples of TMA2 (d) and TMA3 (f). Hazard ratios were calculated using univariate Cox regression. Numbers in brackets indicate 95% confidence interval. P-values were calculated using two-sided Log-Rank test. Abbreviations: HR = hazard ratio, LT = long-term survivors (defined as overall survival > 2.5 years), P = P-value, ST = short-term survivors (defined as patients not belonging to the LT groups), TMA 2 = tissue microarray set 2, TMA 3 = tissue microarray set 3

Back to article page